Sign In
Buy VERX
$12.91
+0.310 (+2.46%)
At Close: Jul 31, 2026
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
12:45pm, Wednesday, 06'th May 2026
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
02:15pm, Tuesday, 05'th May 2026
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
04:04pm, Monday, 04'th May 2026
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Reports First Quarter 2026 Financial Results
04:01pm, Monday, 04'th May 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
01:36pm, Tuesday, 28'th Apr 2026
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
A Look at Vertex Inc (VERX) After 7.2% Gain -- GF Value $35.82 vs Price $12.52
06:10pm, Friday, 24'th Apr 2026
On April 24, 2026, Vertex Inc (VERX) shares rose 7.2% today, currently trading at $12.52. The stock has fluctuated within a 52-week range of $10.59 to $42.44, r
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings
05:57am, Wednesday, 22'nd Apr 2026
Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal, and gene therapies. VRTX's CF franchise continues to grow via ALYFTREK's
Is Vertex Pharmaceuticals' Empire in Trouble?
03:26pm, Thursday, 16'th Apr 2026
Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, Vertex Pharmaceuticals' core franchise looks safe for the foreseeable futu
Vertex to Announce First Quarter 2026 Financial Results on Thursday, May 7, 2026
08:00am, Monday, 13'th Apr 2026
KING OF PRUSSIA, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release fi
Vertex to Announce First Quarter 2026 Financial Results on May 4th
04:00pm, Monday, 06'th Apr 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company
Aberdeen Group plc Cuts Stake in Vertex, Inc. $VERX
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc lessened its stake in Vertex, Inc. (NASDAQ: VERX) by 15.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,221
Vertex, Inc. (NASDAQ:VERX) Given Average Rating of “Hold” by Analysts
02:50am, Sunday, 05'th Apr 2026
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has been given an average rating of "Hold" by the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has
Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand
02:13pm, Thursday, 02'nd Apr 2026
Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. VRTX's new label expansions now cover 95% of U.S.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/
